VASCULAR ENDOTHELIAL GROWTH FACTOR , LIPOPOROTEIN-ASSOCIATED PHOSPHOLIPASE A 2 , SP-SELECTIN AND ANTIPHOSPHOLIPID ANTIBODIES , BIOLOGICAL MARKERS WITH PROGNOSTIC VALUE IN PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND SYSTEMIC LUPUS

No abstract is available for this paper.

• Publication year

  year unknown

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma markers of endothelial dysfunction in type 2 diabetics.

  2006cited by this paper
• Pathophysiological basis for anticoagulant and antithrombotic therapy in pulmonary hypertension.

  2006cited by this paper
• P‐selectin glycoprotein ligand‐1 (PSGL‐1) is up‐regulated on leucocytes from patients with chronic obstructive pulmonary disease

  2005cited by this paper
• Enhanced bronchial expression of vascular endothelial growth factor and receptors (Flk-1 and Flt-1) in patients with chronic obstructive pulmonary disease

  2005cited by this paper
• COPD, a multicomponent disease: implications for management.

  2005cited by this paper
• Phospholipid mediators in the vessel wall: involvement in atherosclerosis

  2005cited by this paper
• Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD.

  2005cited by this paper
• Circulating platelet-derived microparticles in systemic lupus erythematosus

  2005cited by this paper
• , receptors and endogenous PAF synthesis VEGF-mediated endothelial P-selectin translocation : role of VEGF

  2004cited by this paper
• [The significance and treatment of antiphospholipid antibodies].

  2004cited by this paper
• [Pulmonary hypertension associated with systemic lupus erythematosus].

  2004cited by this paper
• Antiphospholipid Syndrome Infectious Origin

  2004cited by this paper
• Cellular and molecular pathobiology of pulmonary arterial hypertension.

  2004cited by this paper
• Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations.

  2004cited by this paper
• Inflammatory response and the endothelium.

  2004cited by this paper
• The significance of human platelet-activating factor-acetylhydrolase in patients with chronic stable angina.

  2004cited by this paper
• Thrombotic disease in systemic lupus erythematosus is associated with a maintained systemic platelet activation

  2004cited by this paper
• Diagnosis and differential assessment of pulmonary arterial hypertension.

  2004cited by this paper
• Platelet activation markers and soluble adhesion molecules in patients with systemic lupus erythematosus

  2004cited by this paper
• Enhanced expression of vascular endothelial growth factor in pulmonary arteries of smokers and patients with moderate chronic obstructive pulmonary disease.

  2003cited by this paper
• Pulmonary vascular involvement in chronic obstructive pulmonary disease

  2003cited by this paper
• Increased neutrophil mediator release in patients with pulmonary hypertension – suppression by inhaled iloprost

  2003cited by this paper
• Simvastatin Rescues Rats From Fatal Pulmonary Hypertension by Inducing Apoptosis of Neointimal Smooth Muscle Cells

  2003cited by this paper
• In vivo platelet activation is associated with increased plasma levels of vascular endothelial growth factor

  2003cited by this paper
• Vascular endothelial growth factor and the risk of smoking-related COPD.

  2003cited by this paper
• [Therapy of pulmonary involvement of rheumatic diseases].

  2003cited by this paper
• Probing antiphospholipid-mediated thrombosis: the interplay between anticardiolipin antibodies and endothelial cells

  2003cited by this paper
• Oxidative stress and apoptosis interact and cause emphysema due to vascular endothelial growth factor receptor blockade.

  2003cited by this paper
• Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension.

  2002cited by this paper
• Increased circulating platelet–leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis

  2001cited by this paper
• Clinical classification of pulmonary hypertension.

  2001cited by this paper
• Thrombogenic Effects of Antiphospholipid Antibodies Are Mediated by Intercellular Cell Adhesion Molecule-1, Vascular Cell Adhesion Molecule-1, and P-Selectin

  2001cited by this paper
• Soluble P-Selectin as a Marker of Platelet Hyperactivity in Patients with Chronic Obstructive Pulmonary Disease

  2000cited by this paper
• Increased Plasma P-Selectin and Decreased Thrombomodulin in Pulmonary Arterial Hypertension Were Improved by Continuous Prostacyclin Therapy

  2000cited by this paper
• Nitric oxide: modulation of the pulmonary circulation.

  2000cited by this paper
• Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity.

  2000cited by this paper
• Proximal pulmonary emboli modify right ventricular ejection pattern.

  1999cited by this paper
• [Erythematosus].

  1971cited by this paper

• Selectins in dermatology

  2011cites this paper